IL-18 inhibition enlarges lesions, necrotic cores and thickens fibrous caps in Jak2 V617F clonal hematopoiesis-driven atherosclerosis., PMID:40501724
Permanent Efferocytosis Prevention by Terminating MerTK Recycle on Tumor-Associated Macrophages for Cancer Immunotherapy., PMID:40294287
Host responses to S. pneumoniae in wild type and Mertk mutant mice., PMID:40238852
Cardiac Macrophages Promote Polarization of Macrophages toward M2 Phenotype to Improve Myocardial Remodeling via NGAL after Myocardial Infarction., PMID:40138155
Activation of proresolving macrophages in dorsal root ganglia attenuates persistent arthritis pain., PMID:40063821
TLR2-Bound Cancer-Secreted Hsp70 Induces MerTK-Mediated Immunosuppression and Tumorigenesis in Solid Tumors., PMID:39941817
ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis., PMID:39570652
Stress-experienced monocytes/macrophages lose anti-inflammatory function via β2-adrenergic receptor in skin allergic inflammation., PMID:39566608
Inflammatory crosstalk impairs phagocytic receptors and aggravates atherosclerosis in clonal hematopoiesis in mice., PMID:39531316
Multimodal Imaging-Assisted Intravascular Theranostic Photoactivation on Atherosclerotic Plaque., PMID:38989585
The Vitamin K-Dependent Anticoagulant Factor, Protein S, Regulates Vascular Permeability., PMID:38666935
A Bispecific Modeling Framework Enables the Prediction of Efficacy, Toxicity, and Optimal Molecular Design of Bispecific Antibodies Targeting MerTK., PMID:38167740
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma., PMID:38105142
Programmed Death Ligand 1-Expressing Macrophages and Their Protective Role in the Joint During Arthritis., PMID:37997621
Correction: Receptor tyrosine kinases Tyro3, Axl, and Mertk differentially contribute to antibody-induced arthritis., PMID:37653485
Targeting MerTK decreases efferocytosis and increases anti-tumor immune infiltrate in prostate cancer., PMID:37644281
Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders., PMID:37545504
Receptor tyrosine kinases Tyro3, Axl, and Mertk differentially contribute to antibody-induced arthritis., PMID:37537628
Macrophage CD5L is a target for cancer immunotherapy., PMID:37054630
A Real-Time Image-Based Efferocytosis Assay for the Discovery of Functionally Inhibitory Anti-MerTK Antibodies., PMID:36881873
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy., PMID:36842467
Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies., PMID:36555321
PEGylation of anti-MerTK Antibody Modulates Ocular Biodistribution., PMID:36153839
The soluble CD83 protein prevents bone destruction by inhibiting the formation of osteoclasts and inducing resolution of inflammation in arthritis., PMID:36003376
Anti-inflammatory clearance of amyloid-β by a chimeric Gas6 fusion protein., PMID:35927581
CTLA4-Ig treatment induces M1-M2 shift in cultured monocyte-derived macrophages from healthy subjects and rheumatoid arthritis patients., PMID:34952630
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study., PMID:34599023
Chronic Porphyromonas gingivalis lipopolysaccharide induces adverse myocardial infarction wound healing through activation of CD8+ T cells., PMID:34597184
Defective Efferocytosis in a Murine Model of Sjögren's Syndrome Is Mediated by Dysfunctional Mer Tyrosine Kinase Receptor., PMID:34575873
Optimization of an Imidazo[1,2-a]pyridine Series to Afford Highly Selective Type I1/2 Dual Mer/Axl Kinase Inhibitors with In Vivo Efficacy., PMID:34478292
Ligand-dependent kinase activity of MERTK drives efferocytosis in human iPSC-derived macrophages., PMID:34035216
MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer., PMID:33562150
Mer tyrosine kinase as a possible link between resolution of inflammation and tissue fibrosis in IgG4-related disease., PMID:33512463
Activated Platelets Convert CD14+CD16- Into CD14+CD16+ Monocytes With Enhanced FcγR-Mediated Phagocytosis and Skewed M2 Polarization., PMID:33488616
TAM receptors: A phosphatidylserine receptor family and its implications in viral infections., PMID:33234246
IgE Activates Monocytes from Cancer Patients to Acquire a Pro-Inflammatory Phenotype., PMID:33203088
Anti-Axl antibody treatment reduces the severity of experimental autoimmune encephalomyelitis., PMID:33121494
MerTK Expression and ERK Activation Are Essential for the Functional Maturation of Osteopontin-Producing Reparative Macrophages After Myocardial Infarction., PMID:32865099
Targeting MerTK Enhances Adaptive Immune Responses After Radiation Therapy., PMID:32311417
MERTK is a host factor that promotes classical swine fever virus entry and antagonizes innate immune response in PK-15 cells., PMID:32172658
TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy., PMID:32087708
Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP., PMID:32049051
Harnessing MerTK agonism for targeted therapeutics., PMID:31852344
Calreticulin and Galectin-3 Opsonise Bacteria for Phagocytosis by Microglia., PMID:31781126
Increased sMer, but not sAxl, sTyro3, and Gas6 relate with active disease in juvenile systemic lupus erythematosus., PMID:31655933
Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses., PMID:31540976
Growth arrest-specific protein 6 (Gas6) attenuates inflammatory injury and apoptosis in iodine-induced NOD.H-2h4 mice., PMID:31129420
A novel human anti-AXL monoclonal antibody attenuates tumour cell migration., PMID:31075180
Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer., PMID:30877108
TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer., PMID:30765874
For research use only. Not for human or drug use.
